Study summary
An IL-17 antibody did not significantly improve remission in GCA
25.6%in sustained remission at 52 weeks with 300 mg, vs 16.9% with placebo
What was tested
Secukinumab, an IL-17A antibody (300 mg or 150 mg) with a 26-week steroid taper, against placebo with a 52-week taper, for giant cell arteritis.
What they found
- Sustained remission at week 52 was 25.6% vs 16.9% (not statistically significant).
- Serious side effects were not higher than with placebo.
What it means
IL-17 blockade did not prove itself in GCA, unlike in its close relative, polymyalgia rheumatica.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.